Trial Profile
A pilot positron emission tomography study to assess striatal adenosine A2A receptor expression in schizophrenia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2022
Price :
$35
*
At a glance
- Drugs SCH 442416 (Primary)
- Indications Schizophrenia
- Focus Diagnostic use
- 01 Nov 2022 Results investigating, using positron emission tomography (PET), the availability of A2A receptors in patients diagnosed with schizophrenia in comparison to matched healthy controls, published in the Psychopharmacology
- 01 Apr 2016 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 12 Mar 2014 New trial record